China NMPA Drug Inspection - Hubei Ruizhe Pharmaceutical Co., Ltd. - Andrographis paniculata slices

The National Medical Products Administration (NMPA) issued an announcement on May 16, 2018, detailing non-compliance issues with four batches of drugs from multiple companies. Testing conducted by various provincial institutes identified significant violations. Shaohuatang Pharmaceutical Co., Ltd. was cited for excessive sulfur dioxide residue in its Angelica dahurica product. Hubei Renyue Pharmaceutical Co., Ltd. faced issues with the content determination of its Andrographis paniculata tablets, and Jilin Shuangxing Pharmaceutical Co., Ltd. similarly failed content determination for its Acanthopanax senticosus tablets. In response, regulatory authorities implemented immediate control measures including product recall, suspension of sales and use, and asset seizure. The NMPA mandated that provincial drug regulatory authorities investigate these companies for illegal activities, including the production and sale of substandard drugs, in accordance with Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. Investigations are required to be completed, and results made public, within three months. This action underscores a commitment to public health and stringent adherence to pharmaceutical quality standards.